Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL) - A Phase I/II Trial With Concomitant Evaluation of Safety and Efficacy.

Trial Profile

Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL) - A Phase I/II Trial With Concomitant Evaluation of Safety and Efficacy.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Alemtuzumab (Primary) ; Bendamustine (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms BendAlem
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Mar 2015 According to the ClinicalTrials.gov record, changed from 1 Jun 2013 to 1 Jun 2015.
    • 06 Mar 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Jun 2013 to 1 Jun 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top